Modelling the progression of illicit substance use patterns from real-world evidence

被引:1
|
作者
Tummala, Hari Prabhath [1 ]
Bies, Robert R. [1 ]
Ramanathan, Murali [1 ,2 ]
机构
[1] Univ Buffalo State Univ New York, Dept Pharmaceut Sci, Buffalo, NY USA
[2] SUNY Buffalo, Dept Pharmaceut Sci, 355 Pharm Bldg, Buffalo, NY 14214 USA
关键词
addiction; disease modeling; drug abuse; pharmacometrics; substance use disorder; MULTISTATE MODELS; OPIOID USE; TRAJECTORIES; SURVIVAL; DRUG; ADDICTION;
D O I
10.1111/bcp.15965
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsTo investigate an innovative pharmacometrics approach that addresses the challenges of using real-world evidence to model the progression of illicit substance use.MethodsThe modelling strategy analysed real-world data from the National Longitudinal Study of Adolescent to Adult Health (AddHealth) survey using survival analyses and differential equations. Respondents were categorized into drug-naive, active users and nonusers. The transitions between categories were modelled using interval-censored parametric survival analysis. The resulting hazard rate functions were used as time-dependent rate constants in a differential equation system. Covariate models for sex and depression status were assessed.ResultsAddHealth enrolled 6504 American teenagers (median age 16 years, range 11-21 years); this cohort was followed with five interviews over a 22-year period; the median age at the last interview was 38 years (range 34-45 years). The percentages of illicit drug users at Interviews 1-5 were 7.7%, 5.9%, 15.8%, 21.4% and 0.98%, respectively. The generalized gamma distribution emerged as the preferred model for the survival functions for transitions between categories. Age-dependent prevalence was obtained from the differential equation system. Active drug use was more prevalent in males, increased in adolescence and college years, peaked at 24 years, and decreased to low levels by 35 years. Depression, which was more frequent in females, increased the drug-naive-active user transition rates but not the active user-nonuser and nonuser-active user transition rates. The evidence did not support an interaction between sex and depression.ConclusionsThe model provided a satisfactory approximation for the age-dependent progression of illicit substance use from preadolescence to early middle age.
引用
收藏
页码:700 / 712
页数:13
相关论文
共 50 条
  • [31] Evidence-based practice in school substance use prevention: fidelity of implementation under real-world conditions
    Ennett, S. T.
    Haws, S.
    Ringwalt, C. L.
    Vincus, A. A.
    Hanley, S.
    Bowling, J. M.
    Rohrbach, L. A.
    HEALTH EDUCATION RESEARCH, 2011, 26 (02) : 361 - 371
  • [32] Editorial: Real-world data and real-world evidence in lung cancer
    Gristina, Valerio
    Eze, Chukwuka
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [33] Editorial: Real-world data and real-world evidence in hematologic malignancies
    Malagola, Michele
    Ohgami, Robert
    Greco, Raffaella
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] When can real-world data generate real-world evidence?
    Rahman, Motiur
    Dal Pan, Gerald
    Stein, Peter
    Levenson, Mark
    Kraus, Stefanie
    Chakravarty, Aloka
    Rivera, Donna R.
    Forshee, Richard
    Concato, John
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [35] Real-world evidence use in assessments of cancer drugs by NICE
    Bullement, Ash
    Podkonjak, Tanja
    Robinson, Mark J.
    Benson, Eugene
    Selby, Ross
    Hatswell, Anthony J.
    Shields, Gemma E.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) : 388 - 394
  • [36] Use of Real-World Evidence in Hematology/Oncology Treatment Optimization
    Vose, Julie M.
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 459 - 459
  • [37] Real-World Evidence: A Primer
    Amit Dang
    Pharmaceutical Medicine, 2023, 37 : 25 - 36
  • [38] Commentary: Real-world Evidence
    Dadds, Mark R.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF FAMILY THERAPY, 2016, 37 (04) : 465 - 466
  • [39] USE OF REAL-WORLD EVIDENCE IN EUROPEAN MEDICINES AGENCY DECISIONS
    Watson, C.
    Jones, G.
    Shaw, C.
    VALUE IN HEALTH, 2022, 25 (12) : S8 - S8
  • [40] Real-World Evidence for Equality
    Johnson, C. Erwin
    Whiteside, Yohance Omar
    HEALTH EQUITY, 2021, 5 (01) : 724 - 726